Recently, researchers found two drugs (nintedanib and pirfenidone) for fatal lung cancer-(diopathic pulmonary fibrosis) firstly. Although the researchers found that these two drugs may not reach the goal of healing the illness, but the drug can alleviate further deterioration of the patient’s condition. The related research has published in the latest issue of the “New England Journal of Medicine”
The incidence of diopathic pulmonary fibrosis in the United States there are about 80,000 cases for each year. Patients suffered this disease are usually with dyspnea and dead 3-4 years after onset. Doctors have no coping strategies to patients suffering from this disorder but to ease the patient’s cough.
Although these drugs do not cure the patient, but many patients still very happy to see it appears because it can not only stabilize the patient’s condition but also prolong the patient’s life span. People have high hopes for these two drugs even through Dr. Gary M. Hunninghake of Brigham and Women’s Hospital, the study’s author, said the drug functioning mechanisms are still not known.
Currently, the drugs haven’t got FDA approval and are still used as experimental drugs. In fact, once suffering from this disease, patients want to know how long he still able to live, they do not care whether the drug is approved by the FDA or not.
The two drugs have side effects, nintedanib can cause diarrhea and pirfenidone may cause eczema and nausea. But the patients seem not care about these side effects when compared with such serious consequences caused by the disease.
In addition, the disease was found not only in smokers but also in some non-smokers.